Sun Pharma entered into an agreement with U.S. government

has entered into an agreement with the U.S. government under which it will extend Most Favoured Nation (MFN) pricing to state Medicaid programmes and apply the framework to future innovative medicine launches. In return, the company has secured a delay of more than two years in the application of Section 232 tariffs on its innovative pharmaceutical products. The agreement provides greater visibility for Sun Pharma’s U.S. innovative-medicines business, which is an important growth driver for the company. The U.S. contributes around 27% of Sun Pharma’s global revenue, while its innovative medicines portfolio accounts for about 22% of sales. The key positive is reduced tariff uncertainty. A more than two-year reprieve gives Sun Pharma additional time to scale its U.S. specialty business without an immediate tariff burden. This is particularly relevant as the company continues to strengthen its presence in higher-value therapies. However, MFN pricing also means lower prices for medicines supplied to Medicaid and potentially lower price realisation on future innovative launches. The exact commercial terms remain confidential, making it difficult to quantify the near-term earnings impact.